De Novo DNA

Executive Summary

De Novo DNA is a San Diego-based synthetic biology and genomics company founded in 2018. The company provides computational tools to calculate transcription, translation, and mRNA decay rates across user-defined systems, enabling researchers to identify cryptic promoters and mis-annotated coding sequences. Additionally, it offers design capabilities for synthetic promoters and ribosome binding sites (RBS) to achieve desired protein expression levels. By streamlining the design-build-test cycle, De Novo DNA aims to accelerate genetic engineering for applications in biomanufacturing, therapeutics, and agriculture. The company's platform addresses critical bottlenecks in predictive modeling of gene expression, a key challenge in synthetic biology. With no disclosed funding or revenue, its technology appears to be in development, targeting academic and industrial labs seeking to optimize gene circuits and metabolic pathways. De Novo DNA operates in the rapidly growing synthetic biology tools market, which is expected to exceed $30 billion by 2030. The company's focus on precise, computationally driven expression tuning positions it competitively against players like Benchling, SynBioBeta, and Desktop Genetics. However, limited public traction—no employee range, stage, or funding details—suggests early-stage operations. Success hinges on validating its platform through partnerships or customer adoption. If De Novo DNA can demonstrate high-accuracy predictions in complex systems, it could become a key enabling technology for the synthetic biology ecosystem. Its potential to reduce trial-and-error experimentation offers significant value, but execution risk remains elevated without visible commercial traction.

Upcoming Catalysts (preview)

• Q3 2026Launch of automated promoter optimization service60% success
• Q4 2026Strategic partnership with a major synthetic biology company40% success
• Q1 2027Publication of validation study with high-profile academic lab70% success